Circle Pharma Inc.

04/29/2025 | Press release | Archived content

Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated in part by disruption of the ATR/CHK1 DNA repair pathway

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Circle Pharma Inc. published this content on April 29, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 02, 2026 at 14:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]